290 research outputs found
Engaging stakeholders in research to address water-energy-food (WEF) nexus challenges
The waterâenergyâfood (WEF) nexus has become a popular, and potentially powerful, frame through which to analyse interactions and interdependencies between these three systems. Though the case for transdisciplinary research in this space has been made, the extent of stakeholder engagement in research remains limited with stakeholders most commonly incorporated in research as end-users. Yet, stakeholders interact with nexus issues in a variety of ways, consequently there is much that collaboration might offer to develop nexus research and enhance its application. This paper outlines four aspects of nexus research and considers the value and potential challenges for transdisciplinary research in each. We focus on assessing and visualising nexus systems; understanding governance and capacity building; the importance of scale; and the implications of future change. The paper then proceeds to describe a novel mixed-method study that deeply integrates stakeholder knowledge with insights from multiple disciplines. We argue that mixed-method research designsâin this case orientated around a number of cases studiesâare best suited to understanding and addressing real-world nexus challenges, with their inevitable complex, non-linear system characteristics. Moreover, integrating multiple forms of knowledge in the manner described in this paper enables research to assess the potential for, and processes of, scaling-up innovations in the nexus space, to contribute insights to policy and decision making
Limb salvage with isolated perfusion for soft tissue sarcoma: could less TNF-α be better?
Background: The optimal dose of TNF-α delivered by isolated limb perfusion (ILP) in patients with locally advanced soft tissue sarcoma is still unknown. Patients and methods: Randomised phase II trial comparing hyperthermic ILP (38-40°) with melphalan and one of the four assigned doses of TNF-α: 0.5âmg, 1âmg, 2âmg, and 3/4âmg upper/lower limb. The main end point was objective tumour response on MRI. Secondary end points were histological response, rate of amputation and toxicity. Resection of the remnant tumour was performed 2-3 months after ILP. The sample size was calculated assuming a linear increase of 10% in the objective response rates between each dose level group. Results: One hundred patients (25 per arm) were included. Thirteen per cent of patients had a systemic leakage with a cardiac toxicity in six patients correlated with high doses of TNF-α. Objective tumour responses were: 68%, 56%, 72% and 64% in the 0.5âmg, 1âmg, 2âmg and 3 or 4âmg arms, respectively (NS). Sixteen per cent of patients were not operated, 71% had a conservative surgery and 13% were amputated with no difference between the groups. With a median follow-up of 24 months, the 2 year overall and disease-free survival rates (95% CI) were 82% (73% to 89%) and 49% (39% to 59%), respectively. Conclusion: At the range of TNF-α doses tested, there was no dose effect detected for the objective tumour response, but systemic toxicity was significantly correlated with higher TNF-α doses. Efficacy and safety of low-dose TNF-α could greatly facilitate ILP procedures in the near futur
Summary of the Standards, Options and Recommendations for the use of positron emission tomography with 2-[18F]fluoro-2-deoxy-D-glucose (FDP-PET scanning) in oncology (2002)
GuidelinePractice GuidelineResearch Support, Non-U.S. Gov'tinfo:eu-repo/semantics/publishe
Large enhancement of the sub-barrier fusion probability for a halo nucleus
The fusion-fission cross sections of the He-4 + U-238 and He-6 + U-238 systems have been measured, at Louvain-la-Neuve, for energies around and below the Coulomb barrier, using an array of Si detectors surrounding a UF4 target. The data taken with 4He are in good agreement with previous data and with the coupled channel fusion calculation performed with ECIS. The He-6 data show a regular trend with a large enhancement below the barrier which is attributed to the halo structure of the He-6 nucleus
Retinoblastoma
Retinoblastoma is a rare eye tumor of childhood that arises in the retina. It is the most common intraocular malignancy of infancy and childhood; with an incidence of 1/15,000â20,000 live births. The two most frequent symptoms revealing retinoblastoma are leukocoria and strabismus. Iris rubeosis, hypopyon, hyphema, buphthalmia, orbital cellulites and exophthalmia may also be observed. Sixty per cent of retinoblastomas are unilateral and most of these forms are not hereditary (median age at diagnosis two years). Retinoblastoma is bilateral in 40% of cases (median age at diagnosis one year). All bilateral and multifocal unilateral forms are hereditary. Hereditary retinoblastoma constitutes a cancer predisposition syndrome: a subject constitutionally carrying an RB1 gene mutation has a greater than 90% risk of developing retinoblastoma but is also at increased risk of developing other types of cancers. Diagnosis is made by fundoscopy. Ultrasound, magnetic resonance imaging (MRI) and computed tomography (CT) scans may contribute to diagnosis. Management of patients with retinoblastoma must take into account the various aspects of the disease: the visual risk, the possibly hereditary nature of the disease, the life-threatening risk. Enucleation is still often necessary in unilateral disease; the decision for adjuvant treatment is taken according to the histological risk factors. Conservative treatment for at least one eye is possible in most of the bilateral cases. It includes laser alone or combined with chemotherapy, cryotherapy and brachytherapy. The indication for external beam radiotherapy should be restricted to large ocular tumors and diffuse vitreous seeding because of the risk of late effects, including secondary sarcoma. Vital prognosis, related to retinoblastoma alone, is now excellent in patients with unilateral or bilateral forms of retinoblastoma. Long term follow-up and early counseling regarding the risk of second primary tumors and transmission should be offered to retinoblastoma patients
Stepping up. What will it take to accelerate a step-change in sustainability for water, energy and food?
Joined-up research can reveal positive, but also
negative impacts of future policy decisions.
Collecting and examining data, engaging stakeholders and
mapping out scenarios across the nexus of water, energy
and food can highlight the unintended negative
consequences of possible future policies as well as the
perceived benefits and these must be accounted for
within the decision-making process.
Blurred boundaries between sectors signal a need
for more integrated planning and management to
tackle environmental challenges.
There needs to be wider acceptance that boundaries
between energy, water and food systems are increasingly
blurred, both physically and politically. Analysis across
these boundaries allows for greater understanding of how
innovations may or may not work. Adaptive forms of
governance can also help, as can a multi-stage decisionmaking process.
Responses to global environmental challenges must
consider a range of contexts.
Policymakers and organisations must ensure that social,
geographical and governance considerations are
factored into decision-making to ensure the successful
uptake and sustainable development of innovations
designed to respond to environmental challenges.
"One size fits all" solutions are unlikely to achieve
sustained success.
Designing context-specific solutions to environmental
problems flexible enough to adapt as conditions and
circumstances change may be complex and challenging
for policymakers, but it offers a more sustainable pathway
than the âone size fits allâ approach often adopted today.
Stakeholder engagement is critical when seeking
solutions to social and environmental challenges.
Giving a range of stakeholders opportunities to reflect,
challenge and contribute throughout a decision-making
process is key to creating a framework that
encompasses a wider context, delivers realistic insights
and avoids the common prioritisation of financial
concerns that can stifle innovation.
Good decision-making requires reflexivity to manage
complexity and uncertainty.
An awareness of the extent to which policy- and decisionmaking within one area of the water-energy-food nexus
can impact other areas can help to mitigate and manage
unintended consequences of those decisions. To support a
step-change in sustainability, governance must find space
for continuous and transdisciplinary reflection.
Relationships between producers, consumers and the
environment matter.
For an innovation to be up-scaled, there is a need
to reconfigure systems of production, provision and
consumption to create space for new emergent systems.
This raises questions over risk, justice, equality, prosperity
and societal wellbeing that researchers and decision makers
must engage with.
To be sustainable, change must be made across
multiple domains.
In order to maximise the potential benefits of innovation in
the areas of water, food and energy, focus must be on
changing socio-tech-environmental conditions in multiple
domains.Engineering and Physical Sciences Research Council (EPSRC
A common polymorphism in NR1H2 (LXRbeta) is associated with preeclampsia
<p>Abstract</p> <p>Background</p> <p>Preeclampsia is a frequent complication of pregnancy and a leading cause of perinatal mortality. Both genetic and environmental risk factors have been identified. Lipid metabolism, particularly cholesterol metabolism, is associated with this disease. Liver X receptors alpha (NR1H3, also known as LXRalpha) and beta (NR1H2, also known as LXRbeta) play a key role in lipid metabolism. They belong to the nuclear receptor superfamily and are activated by cholesterol derivatives. They have been implicated in preeclampsia because they modulate trophoblast invasion and regulate the expression of the endoglin (CD105) gene, a marker of preeclampsia. The aim of this study was to investigate associations between the <it>NR1H3 </it>and <it>NR1H2 </it>genes and preeclampsia.</p> <p>Methods</p> <p>We assessed associations between single nucleotide polymorphisms of <it>NR1H3 </it>(rs2279238 and rs7120118) and <it>NR1H2 </it>(rs35463555 and rs2695121) and the disease in 155 individuals with preeclampsia and 305 controls. Genotypes were determined by high-resolution melting analysis. We then used a logistic regression model to analyze the different alleles and genotypes for those polymorphisms as a function of case/control status.</p> <p>Results</p> <p>We found no association between <it>NR1H3 </it>SNPs and the disease, but the <it>NR1H2 </it>polymorphism rs2695121 was found to be strongly associated with preeclampsia (genotype C/C: adjusted odds ratio, 2.05; 95% CI, 1.04-4.05; <it>p </it>= 0.039 and genotype T/C: adjusted odds ratio, 1.85; 95% CI, 1.01-3.42; <it>p </it>= 0.049).</p> <p>Conclusions</p> <p>This study provides the first evidence of an association between the <it>NR1H2 </it>gene and preeclampsia, adding to our understanding of the links between cholesterol metabolism and this disease.</p
Limb salvage with isolated perfusion for soft tissue sarcoma: could less TNF-alpha be better?
BACKGROUND: The optimal dose of TNF-alpha delivered by isolated limb perfusion (ILP) in patients with locally advanced soft tissue sarcoma is still unknown.
PATIENTS AND METHODS: Randomised phase II trial comparing hyperthermic ILP (38-40 degrees ) with melphalan and one of the four assigned doses of TNF-alpha: 0.5 mg, 1 mg, 2 mg, and 3/4 mg upper/lower limb. The main end point was objective tumour response on MRI. Secondary end points were histological response, rate of amputation and toxicity. Resection of the remnant tumour was performed 2-3 months after ILP. The sample size was calculated assuming a linear increase of 10% in the objective response rates between each dose level group.
RESULTS: One hundred patients (25 per arm) were included. Thirteen per cent of patients had a systemic leakage with a cardiac toxicity in six patients correlated with high doses of TNF-alpha. Objective tumour responses were: 68%, 56%, 72% and 64% in the 0.5 mg, 1 mg, 2 mg and 3 or 4 mg arms, respectively (NS). Sixteen per cent of patients were not operated, 71% had a conservative surgery and 13% were amputated with no difference between the groups. With a median follow-up of 24 months, the 2 year overall and disease-free survival rates (95% CI) were 82% (73% to 89%) and 49% (39% to 59%), respectively.
CONCLUSION: At the range of TNF-alpha doses tested, there was no dose effect detected for the objective tumour response, but systemic toxicity was significantly correlated with higher TNF-alpha doses. Efficacy and safety of low-dose TNF-alpha could greatly facilitate ILP procedures in the near future
- âŠ